February 04, 2010

Jeffrey Keller brings science and business experience to his new part-time position as BNL’s entrepreneur in residence.

December 17, 2009

The Brookhaven Lab team that developed the 2009 R&D 100 Award-winning ProxiScan™, a compact gamma camera that can detect prostate cancer in detail at an early stage, attended a gala awards ceremony at Seaworld, Orlando.

December 10, 2009

Two scientists at Brookhaven Lab have developed a method to control the buildup of hydrogen fluoride gas during the growth of precision crystals needed for applications such as superconductors, optical devices, and microelectronics.

December 01, 2009

BNL’s Technology Maturation Program funds the Laboratory’s researchers with royalties from previously commercialized technologies to prepare new inventions for the marketplace.

November 12, 2009

Brookhaven Lab scientists Ralph James and Yonggang Cui will receive an R&D 100 Award today for the invention of ProxiScan™, a device that can detect prostate cancer in detail at an early stage.

September 15, 2009

Scientists at Brookhaven Lab have patented a new method to remove toxic mercury from soil, sediment, sludge and other industrial waste, allowing mercury to be treated in situ – at its original location in the ground.

July 23, 2009

Brookhaven Lab and Hybridyne Imaging Technologies, Inc., of Toronto, Canada, have won a 2009 R&D 100 Award for developing a compact gamma camera for high-resolution imaging of prostate cancer.

May 28, 2009

Brookhaven was well represented at two conferences earlier this month: Nanotech 2009 and TechConnect Summit 2009, held in conjunction with each other in Houston, Texas, on May 3-7.

May 12, 2009

A Brookhaven Lab physicist has developed a simpler, less-expensive design for delivering tumor-killing particle beams, an invention that could make precision particle therapy available to more cancer patients. The design is available for licensing and commercial development.

March 25, 2009

Scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have developed a method for coating metal surfaces with an ultrathin film containing nanoparticles — particles measuring billionths of a meter — which renders the metal resistant to corrosion and eliminates the use of toxic chromium for this purpose.

February 19, 2009

Brookhaven Science Associates, the company that operates and manages the U.S. Department of Energy’s Brookhaven National Laboratory (BNL), and Biosurface Engineering Technologies, Inc. (BioSET), have been issued a U.S. patent on a synthetic peptide, called B2A.

November 24, 2008

Four physicists at Brookhaven Lab have been awarded U.S. Patent No. 7,432,516 B2 for the design of a “medical synchrotron” capable of delivering precision doses of proton radiation to cancerous tumors with minimal damage to surrounding healthy tissue.

January 25, 2008

Catalyst Pharmaceutical Partners, Inc. announced today that it has initiated enrollment of patients for its 180-patient, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vigabatrin.

December 07, 2007

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced positive initial top-line results from an investigator-initiated Phase II double-blind, placebo-controlled trial, which demonstrates that vigabatrin is effective for the treatment of cocaine addiction. Catalyst's lead compound, CPP-109, is bioequivalent to vigabatrin.

July 10, 2007

Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vig

January 03, 2005

Catalyst Pharmaceutical Partners has announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug Application to evaluate Catalyst_s lead compound, CPP-109, as a potential pharmaceutical therapy for treating cocaine addiction. Catalyst received an exclusive worldwide license from Brookhaven Science Associates, operator of Brookhaven National Laboratory, for the use of the drug gamma vigabatrin or GVG for its application in treating drug addiction.

September 09, 1999

The U.S. Department of Energy's Brookhaven National Laboratory has licensed to David Pharmaceuticals, Inc., of Burlingame, California, the use of the drug vigabatrin for its potential application in treating addiction.